Found: 10
Select item for more details and to access through your institution.
C286, an orally available retinoic acid receptor β agonist drug, regulates multiple pathways to achieve spinal cord injury repair.
- Published in:
- Frontiers in Molecular Neuroscience, 2024, p. 1, doi. 10.3389/fnmol.2024.1411384
- By:
- Publication type:
- Article
Drug repurposing for Alzheimer's disease based on transcriptional profiling of human iPSC-derived cortical neurons.
- Published in:
- Translational Psychiatry, 2019, v. 9, n. 1, p. N.PAG, doi. 10.1038/s41398-019-0555-x
- By:
- Publication type:
- Article
Conserved residues within the putative active site of γ-secretase differentially influence enzyme activity and inhibitor binding.
- Published in:
- Journal of Neurochemistry, 2004, v. 90, n. 6, p. 1312, doi. 10.1111/j.1471-4159.2004.02596.x
- By:
- Publication type:
- Article
Regulation of Myelination by Exosome Associated Retinoic Acid Release from NG2-Positive Cells.
- Published in:
- Journal of Neuroscience, 2019, v. 39, n. 16, p. 3013, doi. 10.1523/JNEUROSCI.2922-18.2019
- By:
- Publication type:
- Article
Neuronal RARβ Signaling Modulates PTEN Activity Directly in Neurons and via Exosome Transfer in Astrocytes to Prevent Glial Scar Formation and Induce Spinal Cord Regeneration.
- Published in:
- Journal of Neuroscience, 2015, v. 35, n. 47, p. 15731, doi. 10.1523/JNEUROSCI.1339-15.2015
- By:
- Publication type:
- Article
S2-03-02: Mechanistic differences in targeting γ-secretase with inhibitors
- Published in:
- 2006
- By:
- Publication type:
- Abstract
S2-03-02: Mechanistic differences in targeting γ-secretase with inhibitors
- Published in:
- 2006
- By:
- Publication type:
- Abstract
Amyloid β inhibits retinoic acid synthesis exacerbating Alzheimer disease pathology which can be attenuated by an retinoic acid receptor α agonist.
- Published in:
- European Journal of Neuroscience, 2013, v. 37, n. 7, p. 1182, doi. 10.1111/ejn.12142
- By:
- Publication type:
- Article
An embryological tumor of retinal anlage involving the skull.
- Published in:
- 1951
- By:
- Publication type:
- journal article
Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL‐286, a novel retinoic acid receptor‐β agonist for treatment of spinal cord injury, in male healthy participants.
- Published in:
- British Journal of Clinical Pharmacology, 2023, v. 89, n. 12, p. 3573, doi. 10.1111/bcp.15854
- By:
- Publication type:
- Article